Clinical Trial Update: Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Basiliximab versus low-dose Thymoglobulin induction therapy in low-risk kidney transplant patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant

Drugs mentioned

• Basiliximab (basiliximab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Coordinación de Investigación en Salud, Mexico | Conditions: Kidney Transplant Rejection, Kidney Transplant; Complications | Phase 4 | Status: COMPLETED